Next Article in Journal
Contribution of Epigenetic Modifications to the Decline in Transgene Expression from Plasmid DNA in Mouse Liver
Previous Article in Journal
Neurosurgical Techniques for Disruption of the Blood–Brain Barrier for Glioblastoma Treatment
Article Menu

Export Article

Open AccessArticle
Pharmaceutics 2015, 7(3), 188-198; doi:10.3390/pharmaceutics7030188

Influence of Differing Analgesic Formulations of Aspirin on Pharmacokinetic Parameters

1
School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA
2
Bayer HealthCare, 100 Bayer Blvd, Whippany, NJ 07981, USA
3
Bayer HealthCare, Building K56, 51368 Leverkusen, Germany
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Afzal R. Mohammed
Received: 25 June 2015 / Revised: 29 July 2015 / Accepted: 29 July 2015 / Published: 3 August 2015
(This article belongs to the Special Issue Drug Metabolism and Pharmacokinetics)
View Full-Text   |   Download PDF [1330 KB, uploaded 3 August 2015]   |  

Abstract

Aspirin has been used therapeutically for over 100 years. As the originator and an important marketer of aspirin-containing products, Bayer’s clinical trial database contains numerous reports of the pharmacokinetics of various aspirin formulations. These include evaluations of plain tablets, effervescent tablets, granules, chewable tablets, and fast-release tablets. This publication seeks to expand upon the available pharmacokinetic information concerning aspirin formulations. In the pre-systemic circulation, acetylsalicylic acid (ASA) is rapidly converted into its main active metabolite, salicylic acid (SA). Therefore, both substances are measured in plasma and reported in the results. The 500 mg strength of each formulation was chosen for analysis as this is the most commonly used for analgesia. A total of 22 studies were included in the analysis. All formulations of 500 mg aspirin result in comparable plasma exposure to ASA and SA as evidenced by AUC. Tablets and dry granules provide a consistently lower Cmax compared to effervescent, granules in suspension and fast release tablets. Effervescent tablets, fast release tablets, and granules in suspension provide a consistently lower median Tmax compared to dry granules and tablets for both ASA and SA. This report reinforces the importance of formulation differences and their impact on pharmacokinetic parameters. View Full-Text
Keywords: clinical pharmacokinetics; pharmacokinetics; absorption; formulation; prodrugs; aspirin clinical pharmacokinetics; pharmacokinetics; absorption; formulation; prodrugs; aspirin
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kanani, K.; Gatoulis, S.C.; Voelker, M. Influence of Differing Analgesic Formulations of Aspirin on Pharmacokinetic Parameters. Pharmaceutics 2015, 7, 188-198.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top